First targeted treatment for Guillain-Barré syndrome nears approval

Three weeks after a stomach bug or a bout of the flu, a person wakes with tingling in their feet. Within hours the tingling climbs their legs; within days they may be on a ventilator, their diaphragm failing. That person could be anyone of any age, and the trigger could be almost any common infection. For them, a new drug called tanruprubart may finally offer what medicine has never offered in Guillain-Barré syndrome: a single infusion that turns off the part of the immune system that drives the body to attack its own nerves.

Guillain-Barré is rare, hitting about one or two people per 100,000 each year, but it is indiscriminate in whom it strikes. It can follow a Campylobacter infection from undercooked chicken, a Zika case, even a routine bout of flu. The mechanism is what makes the disease strange. Antibodies built to fight the original infection end up matching proteins on the lining of peripheral nerves, and the immune system then strips those nerves bare. The damage climbs from the feet upward, sometimes halting at the legs, sometimes reaching the muscles that control breathing. Recovery can take months. Some patients never fully walk again.

What medicine offers today is supportive rather than curative. Plasma exchange and intravenous immunoglobulin, the immune-bulk treatments known as IVIG, blunt the attack on the body's own nerves without addressing the molecular driver. Ventilators keep people alive while the nerves slowly rebuild. A clinical commentary in ACNR notes that no therapy in routine use actually targets the complement cascade that strips the myelin sheath, which is why a first-of-kind candidate is a real event rather than a marketing line.

Tanruprubart, developed by Annexon Biosciences, tries to be that brake. It is a monoclonal antibody, a lab-made immune protein, that latches onto a protein called C1q, the first domino in a chain reaction immunologists call the classical complement pathway. In healthy immune defense, C1q flags pathogens and infected cells for destruction. In Guillain-Barré, the same cascade gets misdirected at the body's own nerve coverings. A pathophysiology review in PMC lays out the case: C1q is deposited on peripheral nerve fibers in patients with the disease, and blocking it early in animal models stops the cascade before the myelin sheath is stripped. The drug's bet is that the same brake, applied within the first two weeks of symptoms, will preserve the nerve before the worst damage is done.

The Phase 3 test of that bet, run in Bangladesh and the Philippines and reported by New Scientist, enrolled 241 patients within roughly ten days of symptom onset. Half got a single intravenous infusion of tanruprubart; half got placebo, on top of whatever supportive care their hospital provided. The headline numbers, presented in June at the Congress of the European Academy of Neurology in Geneva, were unusually stark for a neurology trial. The treated group spent 28 fewer days on mechanical ventilation, 7 fewer days in intensive care, and walked independently 31 days sooner. A higher share of treated patients described themselves as "very much improved" at one week. Quality-of-life and mobility scores at two months tracked the same direction. No serious adverse events were attributed to the infusion in the trial window.

The developer, Annexon, announced the topline readout and, on the strength of it, filed a Marketing Authorization Application with the European Medicines Agency in the same quarter, a path that could put the drug on the European market as early as next year if regulators agree. There is no equivalent filing in the United States yet; Annexon has said it is in discussions with the FDA about next steps.

Both trial sites were in Bangladesh and the Philippines, where Guillain-Barré is more common and where ICU care, baseline nutrition, and the mix of triggering infections differ from higher-income settings. Conference-stage readouts also lack the granular peer review a published manuscript would carry, and the full Phase 3 paper has not yet appeared. Annexon's own commentary has been measured. The New Scientist write-up describes the result as the drug having "worked well," not as a cure.

Two longer questions are also still open. C1q blockade is a deliberate suppression of one branch of the immune system, and the trial follow-up is short. Whether a single infusion leaves patients more vulnerable to infection months or years later is the kind of question only post-market surveillance can answer. And the cost of biologic drugs for rare diseases has become its own fight. Tanruprubart is being positioned for a disease with no good alternatives, but Annexon has not yet disclosed pricing, and European health systems will weigh the new therapy against decades of relatively cheap IVIG and plasma exchange.

What is not in dispute is that, for the first time, a candidate drug for Guillain-Barré acts on the molecule most directly responsible for nerve damage rather than on the immune system at large. The next checkpoint is a European regulator's decision on the filing; the next data point, the full Phase 3 manuscript.